Literature DB >> 2654356

Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.

M Hammarlund-Udenaes1, L Z Benet.   

Abstract

The literature on furosemide pharmacokinetics and pharmacodynamics is critically reviewed, concentrating on those papers published subsequent to the 1979 reviews of this topic. Intravenous and oral data are presented for healthy volunteers and for patients with various disease states. It is the latter populations about which the majority of the studies have been published since 1979. Inter- and intraindividual variations in bioavailability are discussed, as are data on the metabolism of furosemide to its glucuronide conjugate. Published studies examining the relationship between furosemide pharmacodynamics and pharmacokinetics are also evaluated. The literature is reviewed through June 1988.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2654356     DOI: 10.1007/bf01059086

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  99 in total

1.  Reduced bioavailability and effect of furosemide given with food.

Authors:  B Beermann; C Midskov
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Pharmacokinetics of orally administered furosemide.

Authors:  M R Kelly; R E Cutler; A W Forrey; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

3.  Effect of dosage regimen on natriuretic response to furosemide.

Authors:  T W Wilson; K J Falk; J L Labelle; K B Nguyen
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

4.  Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.

Authors:  A Rakhit; G M Kochak; V Tipnis; M E Hurley
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

5.  Furosemide kinetics and dynamics in aged patients.

Authors:  A L Kerremans; Y Tan; H van Baars; C A van Ginneken; F W Gribnau
Journal:  Clin Pharmacol Ther       Date:  1983-08       Impact factor: 6.875

6.  Disposition and absolute bioavailability of furosemide in healthy males.

Authors:  E S Waller; S F Hamilton; J W Massarella; M A Sharanevych; R V Smith; G J Yakatan; J T Doluisio
Journal:  J Pharm Sci       Date:  1982-10       Impact factor: 3.534

7.  Furosemide assays and disposition in healthy volunteers and renal transplant patients.

Authors:  L Z Benet; D E Smith; E T Lin; F Vincenti; J G Gambertoglio
Journal:  Fed Proc       Date:  1983-04

8.  Furosemide disposition in cirrhosis.

Authors:  R K Verbeeck; R V Patwardhan; J P Villeneuve; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1982-06       Impact factor: 6.875

9.  Implications of intraindividual variability in bioavailability studies of furosemide.

Authors:  A Grahnén; M Hammarlund; T Lundqvist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Biotransformation of furosemide in kidney transplant patients.

Authors:  D E Smith; L Z Benet
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more
  27 in total

1.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

2.  The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs.

Authors:  Mehran Yazdanian; Katherine Briggs; Corinne Jankovsky; Amale Hawi
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

3.  The validity of the sigmoid Emax model and efficiency concept in diuretic studies.

Authors:  G Alván; M Hammarlund-Udenaes; B Odlind
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

4.  Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults.

Authors:  J J van Meyel; Y Tan; P Smits; F G Russel; C A van Ginneken; F W Gribnau
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

Review 6.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

7.  The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit.

Authors:  V Pichette; D Geadah; P du Souich
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 8.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

9.  Sublingual administration of furosemide: new application of an old drug.

Authors:  Laurent Haegeli; Hans Peter Brunner-La Rocca; Markus Wenk; Matthias Pfisterer; Jürgen Drewe; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335

Review 10.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.